SELLAS Life Sciences Gr Q3 EPS $(0.05), Inline
SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SLS Stock Rises After-Hours: State Street Reveals Over 5% Stake — And One Fund Manager Boosted Holdings By Nearly 1,000%
SLS Stock Rises Overnight: Retail Bets The Regal Wait Is Almost Over — Here’s What Wall Street Expects From Earnings
SELLAS Life Sciences Group (SLS) Stock Could Be Fully Priced On Phase 3 Analysis Trigger
Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
SELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400%
SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?
SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?
Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%
Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final Data
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
SELLAS Life Sciences Stock Stumbles: What's Going On?
SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event
Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure
SLS Stock Gets A BlackRock Spotlight Ahead Of Phase 3 AML Data — Bulls Spot 2027 European GPS Approval Forecast
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.